scispace - formally typeset
L

Louise A. Knight

Researcher at Queen Alexandra Hospital

Publications -  24
Citations -  708

Louise A. Knight is an academic researcher from Queen Alexandra Hospital. The author has contributed to research in topics: Chemosensitivity assay & Cisplatin. The author has an hindex of 16, co-authored 24 publications receiving 663 citations. Previous affiliations of Louise A. Knight include University of Portsmouth.

Papers
More filters
Journal ArticleDOI

Heterogeneity of chemosensitivity of esophageal and gastric carcinoma.

TL;DR: The degree of heterogeneity observed suggests that the ATP-TCA could be used to individualize chemotherapy by selecting agents for particular patients, and provides the rationale for a trial of ATP- TCA-directed therapy to determine whether individualization of chemotherapy might improve patient response and survival.
Journal ArticleDOI

Ex vivo reversal of chemoresistance by tariquidar (XR9576).

TL;DR: The results show that tariquidar is able to decrease resistance in a number of solid tumors resistant to cytotoxic drugs known to be P-gp substrates, and support the introduction of tarLiquidar in combination with chemotherapy to clinical trials of patients expressing P- gp.
Journal ArticleDOI

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy

TL;DR: The chemosensitivity of ovarian cancer to drugs is related to the expression of genes involved in sensitivity and resistance mechanisms, and particularly strong correlations were obtained for cisplatin, gemcitabine, topotecan, and treosulfan+gem citabine.
Journal ArticleDOI

Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.

TL;DR: The results suggest that the use of appropriate culture conditions i.e. a serum-free culture environment, adherence-free growth and optimum seeding density can induce cell lines to behave more like tumour-derived cells in response to cytotoxic agents.
Journal Article

The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples

TL;DR: Data support the rapid introduction of XR5944 to clinical trials and suggest that it may be effective against a broad spectrum of tumor types, especially ovarian and breast cancer.